Skip to content
Strength & muscleResearch article3 min read

Older adults with type 2 diabetes: sarcopenia more common in women, and less with metformin

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Risk Factors for Sarcopenia in the Elderly with Type 2 Diabetes Mellitus and the Effect of Metformin. · Journal of diabetes research · 2020 · Original paper ↗

Key takeaway

Among 1732 older adults with type 2 diabetes, 10.37% had sarcopenia, and metformin users had lower odds than people taking no medication (OR 0.510 for metformin alone, 0.398 combined with other drugs). This is a cross-sectional snapshot, so it cannot show that metformin protects muscle.

Study design

Research article

Reading basis

Published abstract

Reading focus

Design & applicability

The research question

Sarcopenia, the loss of muscle mass and function, is common in older people and especially in those with type 2 diabetes. The authors set out to identify risk factors for sarcopenia in older adults with type 2 diabetes and to see whether metformin use was related to it.

Who and how

Cross-sectional observational study of 1732 older adults with type 2 diabetes, analyzed with logistic regression. Sarcopenia was diagnosed from skeletal muscle mass, grip strength and usual gait speed, using the criteria of the Asian Working Group for Sarcopenia combined with a Chinese expert consensus. The abstract does not report the setting or how muscle mass was measured.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Overall, 10.37% of participants had sarcopenia.
  2. 2
    In the multivariate analysis, sex, age, educational level and BMI were risk factors. Women were more likely to have sarcopenia than men (OR 2.539, 95% CI 1.475-4.371; P<0.05). Sarcopenia became more common with age and less common with higher BMI and education (P<0.05).
  3. 3
    People taking metformin alone (OR 0.510, 95% CI 0.288-0.904) or with other drugs (OR 0.398, 95% CI 0.225-0.702) had lower odds of sarcopenia than people taking no medication (P<0.05).

Limits & uncertainty

  1. 1
    Because exposure and outcome were measured at one time point, the study cannot tell whether metformin lowers sarcopenia risk or whether healthier people are simply more likely to be prescribed it.
  2. 2
    The comparison group was people taking no medication, who may differ from drug users in diabetes duration and severity. The abstract does not say what else was adjusted for.
  3. 3
    Sarcopenia was fairly uncommon (10.37%), so subgroup estimates may be imprecise, and the criteria were Asian and Chinese, which limits use for other populations.
  4. 4
    Calling metformin a protective agent goes beyond what this design shows. This reading is based on the abstract only.

What to take from it

If you are older and have type 2 diabetes, muscle strength and body weight are worth watching, especially for women, people of older age and people with a lower BMI. The metformin finding is an association and is not a reason to start, stop or change any medication. Talk to your clinician about diabetes treatment and muscle health.

Reading your own data

Useful personal data include body weight and grip or chair-rise performance measured in the same way over time. Wearable step counts and activity can show whether you stay active, but they do not measure muscle mass.

How to read this evidence

The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Aims

Sarcopenia is a common condition in older individuals, especially in the elderly with type 2 diabetes mellitus (T2DM). The aim of the present study was to examine the risk factors for sarcopenia in elderly individuals with T2DM and the effects of metformin.

Methods

A total of 1732 elderly with T2DM were recruited to this cross-sectional observational study, and we analyzed the data using logistic regression analyses. Skeletal muscle mass, grip strength, and usual gait speed were measured to diagnose sarcopenia according to the criteria of the Asian Working Group for Sarcopenia, combined with expert consensus on sarcopenia in China.

Results

The overall prevalence of sarcopenia was 10.37% of the participants. In the multivariate analysis, sex, age, educational level, and BMI were risk factors for sarcopenia, with women more likely to develop sarcopenia relative to men (OR = 2.539, 95% CI = 1.475-4.371; P < 0.05). We observed that sarcopenia increased with age and decreased with increasing BMI and educational level ( P < 0.05). Participants who took metformin alone or combined with other drugs exhibited a lower risk for sarcopenia than those who took no medication (OR = 0.510, 95% CI = 0.288-0.904 and OR = 0.398, 95% CI = 0.225-0.702, respectively; P < 0.05).

Conclusions

We showed that being female and at an older age, lower educational level, and lower BMI were risk factors for sarcopenia in elderly T2DM and that metformin acted as a protective agent against sarcopenia in these patients.

Sources & attribution

Risk Factors for Sarcopenia in the Elderly with Type 2 Diabetes Mellitus and the Effect of Metformin.

Chen F, Xu S, Wang Y, Chen F, Cao L, Liu T, Huang T, Wei Q, Ma G, Zhao Y, Wang D.

Journal of diabetes research · 2020-10-07

DOI: 10.1155/2020/3950404 ↗PubMed · 33083494 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Overview of reviews

ACSM review of 137 reviews: resistance training works, and few programme details matter

The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.

Medicine & Science in Sports & Exercise

In-depth explainersRead study →
·Trial meta-analysis

Nearly every resistance training plan beat no exercise; heavy loads led for strength

In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.

British Journal of Sports Medicine

In-depth explainersRead study →
·Observational meta-analysis

Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes

Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.

British Journal of Sports Medicine

In-depth explainersRead study →
·Trial meta-analysis

Protein supplements and weight training: small extra gains, smaller in older adults

Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.

British Journal of Sports Medicine

In-depth explainersRead study →
Strength & muscle →